ZAP-70+ B cell subset influences response to B cell depletion therapy and early repopulation in rheumatoid arthritis

Journal of Rheumatology

Volumn 39, Issue 12, 2012, Pages 2276-2285

  Gremese, Elisa ^a   Tolusso, Barbara ^a   Fedele, Anna Laura ^b   Canestri, Silvia ^b   Alivernini, Stefano ^b   Ferraccioli, Gianfranco ^b  

^a Cellular and Molecular Research Laboratory   (Italy)

^b UNIVERSITÀ CATTOLICA DEL SACRO CUORE   (Italy)

Author keywords

B cell subsets; Biomarkers; Depletion therapy; Rheumatoid arthritis; Rituximab; ZAP 70

Indexed keywords

C REACTIVE PROTEIN; CD19 ANTIGEN; CD27 ANTIGEN; CD3 ANTIGEN; CD38 ANTIGEN; CD45 ANTIGEN; CD56 ANTIGEN; CHLOROQUINE; IMMUNOGLOBULIN D; LEFLUNOMIDE; METHOTREXATE; PREDNISONE; PROTEIN KINASE ZAP 70; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOFLUOROMETRY; DISEASE ACTIVITY; DISEASE DURATION; DRUG RESPONSE; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; HUMORAL IMMUNE DEFICIENCY; IMMUNOPHENOTYPING; IMMUNOTHERAPY; LEUKOCYTE COUNT; LOW DRUG DOSE; MALE; MEMORY CELL; OUTCOME ASSESSMENT; PHENOTYPE; POPULATION DYNAMICS; PRIORITY JOURNAL; PROTEIN FUNCTION; QUESTIONNAIRE; RECEIVER OPERATING CHARACTERISTIC; RELAPSE; RHEUMATOID ARTHRITIS;

ARTHRITIS, RHEUMATOID; B-LYMPHOCYTE SUBSETS; BIOLOGICAL MARKERS; CYTOPLASM; FEMALE; HEALTH STATUS; HUMANS; INTERLEUKIN-6; JOINTS; LYMPHOCYTE COUNT; LYMPHOCYTE DEPLETION; MALE; MIDDLE AGED; PLASMA CELLS; QUESTIONNAIRES; TREATMENT OUTCOME; ZAP-70 PROTEIN-TYROSINE KINASE;

EID: 84870360376     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.120153     Document Type: Article

References (35)

1. Quinn MA, Emery P. Window of opportunity in early rheumatoid arthritis: Possibility of altering the disease process with early intervention. Clin Exp Rheumatol 2003;21:S154-7. (Pubitemid 37265605)
2. van de Sande MG, de Hair MJ, van der Leij C, Klarenbeek PL, Bos WH, Smith MD, et al. Different stages of rheumatoid arthritis: Features of the synovium in the preclinical phase. Ann Rheum Dis 2011;70:772-7.
3. Hazes JM, Luime JJ. The epidemiology of early inflammatory arthritis. Nat Rev Rheumatol 2011;7:381-90.
4. Martin F, Chan AC. B cell immunobiology in disease: Evolving concepts from the clinic. Annu Rev Immunol 2006;24:467-96.
5. Edwards JC, Leandro MJ, Cambridge G. B lymphocyte depletion in rheumatoid arthritis: Targeting of CD20. Curr Dir Autoimmun 2005;8:175-92.
6. Hoyer BF, Manz RA, Radbruch A, Hiepe F. Long-lived plasma cells and their contribution to autoimmunity. Ann NY Acad Sci 2005;1050:124-33. (Pubitemid 41129429)
7. De Vita S, Zaja F, Sacco S, De Candia A, Fanin R, Ferraccioli G. Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: Evidence for a pathogenetic role of B cells. Arthritis Rheum 2002;46:2029-33.
8. Chynes RA, Towers TL, Presta LG. Inhibitory Fc receptors modulate in-vivo cytotoxicity against tumor targets. Nat Med 2006;6:443-6.
9. Thurlings RM, Vos K, Wijbrandts CA, Zwinderman AH, Gerlag DM, Tak PP. Synovial tissue response to rituximab: Mechanism of action and identification of biomarkers of response. Ann Rheum Dis 2008;67:917-25. (Pubitemid 351956651)
10. Vos K, Thurlings RM, Wijbrandts CA, van Schaardenburg DJ, Gerlag DM, Tak PP. Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis. Arthritis Rheum 2007;56:772-8. (Pubitemid 46399424)
11. Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland ML, Tarp U, et al. Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: Pooled data from 10 European registries. Ann Rheum Dis 2011;70:1575-80.
12. Vital EM, Rawstron AC, Dass S, Henshaw K, Madden J, Emery P, et al. Reduced-dose rituximab in rheumatoid arthritis: Efficacy depends on degree of B cell depletion. Arthritis Rheum 2011;63:603-8.
13. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572-81. (Pubitemid 38758544)
14. Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006;54:1390-400.
15. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, at al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2793-806. (Pubitemid 44497758)
16. Anolik JH, Looney RJ, Lund FE, Randall TD, Sanz I. Insights into the heterogeneity of human B cells: Diverse functions, roles in autoimmunity, and use as therapeutic targets. Immunol Res 2009,45:144-58.
17. Silverman GJ. Therapeutic B cell depletion and regeneration in rheumatoid arthritis: Emerging patterns and paradigms. Arthritis Rheum 2006;54:2356-67. (Pubitemid 44204995)
18. Roll P, Palanichamy A, Kneitz C, Dorner T, Tony HP. Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Arthritis Rheum 2006;54:2377-86. (Pubitemid 44204997)
19. Elder ME, Lin D, Clever J, Chan AC, Hope TJ, Weiss A, et al. Human severe combined immunodeficiency due to a defect in ZAP-70, a T cell tyrosine kinase. Science 1994;264:1596-9. (Pubitemid 24227716)
20. Gobessi S, Laurenti L, Longo PG, Sica S, Leone G, Efremov DG. ZAP-70 enhances B-cell-receptor signaling despite absent or inefficient tyrosine kinase activation in chronic lymphocytic leukemia and lymphoma B cells. Blood 2007;109:2032-9. (Pubitemid 46348203)
21. Tolusso B, De Santis M, Bosello S, Gremese E, Gobessi S, Cuoghi I, et al. Synovial B cells of rheumatoid arthritis express ZAP-70 which increases the survival and correlates with the inflammatory and autoimmune phenotype. Clin Immunol 2009;131:98-108.
22. Michelutti A, Gremese E, Morassi F, Petricca L, Arena V, Tolusso B, et al. B cell subsets in the joint compartments of seropositive and seronegative RA and non-RA arthritides express memory markers and ZAP-70 and characterize the aggregate pattern irrespectively of the autoantibody status. Mol Med 2011;17:901-9.
23. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24. (Pubitemid 18091653)
24. van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996;39:34-40. (Pubitemid 26036375)
25. Youinou P. B cells conduct the lymphocyte orchestra. J Autoimmunity 2007;28:143-51.
26. Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, Rozman M, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003;348:1764-75. (Pubitemid 36514707)
27. Isaacs JD, Ferraccioli G. The need for personalised medicine for rheumatoid arthritis. Ann Rheum Dis 2011;70:4-7.
28. Buch MH, Rubbert-Roth A, Ferraccioli G. To switch or not to switch after a poor response to a TNF-α blocker? It is not only a matter of ACR20 OR ACR50. Autoimmun Rev 2012;11:558-62.
29. Roll P, Dörner T, Tony HP. Anti-CD20 therapy in patients with rheumatoid arthritis: Predictors of response and B cell subset regeneration after repeated treatment. Arthritis Rheum 2008;58:1566-75. (Pubitemid 351847509)
30. Nakou M, Katsikas G, Sidiropoulos P, Bertsias G, Papadimitraki E, Raptopoulou A, et al. Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: Depletion of memory B cells correlates with clinical response. Arthritis Res Ther 2009;11:R131.
31. Sellam J, Rouanet S, Hendel-Chavez H, Abbed K, Sibilia J, Tebib J, et al. Blood memory B cells are disturbed and predict the response to rituximab in patients with rheumatoid arthritis. Arthritis Rheum 2011;63:3692-701.
32. Rehnberg M, Amu S, Tarkowski A, Bokarewa MI, Brisslert M. Short- and long-term effects of anti-CD20 treatment on B cell ontogeny in bone marrow of patients with rheumatoid arthritis. Arthritis Res Ther 2009;11:R123.
33. Anolik JH, Barnard J, Cappione A, Pugh-Bernard AE, Felgar RE, Looney RJ, et al. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum 2004;50:3580-90. (Pubitemid 39488683)
34. Calpe E, Codony C, Baptista MJ, Abrisqueta P, Carpio C, Purroy N, et al. ZAP-70 enhances migration of malignant B lymphocytes toward CCL21 by inducing CCR7 expression via IgM-ERK1/2 activation. Blood 2011;118:4401-10.
35. Chen L, Huynh L, Apgar J, Tang L, Rassenti L, Weiss A, et al. ZAP-70 enhances IgM signaling independent of its kinase activity in chronic lymphocytic leukemia. Blood 2008;111:2685-92.